Acid-Suppression Medicines in Veterinary Oncology: Rational-Use Profile

proton-pump inhibitors and histamine-2 receptor antagonists is covered as gastrointestinal supportive-medicine class, with species, evidence, regulatory, safety, interaction and monitoring boundaries for a veterinarian-led decision.

Gastrointestinal supportive-medicine class. Class examples include omeprazole-type proton-pump inhibitors and famotidine-type H2-receptor antagonists; individual products are not interchangeable.

Class examples include omeprazole-type proton-pump inhibitors and famotidine-type H2-receptor antagonists; individual products are not interchangeable.

Proton-pump inhibitors suppress the final step of gastric acid secretion, while H2 antagonists reduce histamine-mediated acid secretion. Neither class is a general anti-nausea drug or anticancer treatment.

AAHA lists antacids among other gastrointestinal support. The ACVIM consensus supports rational use for acid-related disease and challenges routine administration without ulceration, bleeding risk or reflux-related indications.

AAHA lists antacids among other gastrointestinal support. The ACVIM consensus supports rational use for acid-related disease and challenges routine administration without ulceration, bleeding risk or reflux-related indications.

Oral or injectable medicines selected for a defined gastrointestinal indication

Evidence for effective acid suppression and clinical benefit differs by drug, species, indication and duration. Routine prophylaxis for every chemotherapy patient is not evidence-based.

Unnecessary or prolonged suppression may alter gastrointestinal flora, nutrient handling and drug absorption. Abrupt discontinuation after prolonged proton-pump inhibition can be clinically relevant. Kidney, liver and concurrent gastrointestinal disease affect selection.

Acid-dependent oral medicines, sucralfate and other products may require timing decisions. An H2 blocker used as a labelled companion medicine around mast-cell degranulation is a different context from chronic acid suppression.

This is a class overview, not a statement that every human product is approved for dogs or cats. Local veterinary labels and extra-label rules apply.

Multi-region use; medicine-specific authorisation varies.

First define the target problem: ulceration, reflux, bleeding risk or another diagnosis. Track vomiting, regurgitation, stool colour, appetite and relevant laboratory findings. Black stool, blood, collapse or persistent vomiting requires urgent assessment. The veterinarian defines duration and any taper.